Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Australian Stock Exchange  >  Mesoblast Limited    MSB   AU000000MSB8

MESOBLAST LIMITED

(MSB)
  Report
End-of-day quote. End-of-day quote Australian Stock Exchange - 11/24
4.47 AUD   +4.44%
11/24MESOBLAST : Chairman Message to 2020 AGM
AQ
11/24MESOBLAST : Results of Meeting
PU
11/24MESOBLAST : Chairman Message to 2020 AGM
PU
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

Mesoblast : Annual Report to shareholders

10/25/2020 | 11:45pm EST

ANNUAL REPORT 2020

GLOBAL LEADER

IN ALLOGENEIC CELLULAR MEDICINES FOR INFLAMMATORY DISEASES

CONTENTS

MESSAGE FROM THE CHAIRMAN

1

FORM 20-F

2

SHAREHOLDER INFORMATION

228

CORPORATE DIRECTORY

230

CORPORATE GOVERNANCE

Mesoblast Limited and its Board of Directors are committed to implementing and achieving an effective corporate governance framework to ensure that the Company is managed effectively and in an honest and ethical way.

The Company's Corporate Governance statement for the financial year ending 30 June 2020 has been approved by the Board and is available on our website at http://www.mesoblast.com/company/corporate-governance

MESSAGE FROM THE CHAIRMAN

Joseph R. Swedish

Chairman

Dear shareholders,

This has been an unprecedented year due to the coronavirus pandemic, its impact on human health, and the economic consequences it has wrought. The Mesoblast leadership responded with great agility and resilience to this urgent challenge, creatively applying our technology platform to develop a potential treatment for moderate to severe acute respiratory distress syndrome (ARDS) due to COVID-19.

Through a deep understanding of the science, and utilizing the clinical and regulatory teachings gained from years of meticulous development, our team has harnessed the anti- inflammatory and reparative properties of our mesenchymal lineage cell technology.

The original indication for which our lead allogeneic cell therapy remestemcel-L was developed, pediatric steroid-refractory acute graft versus host disease (SR-aGVHD), has a shared mechanism of action with COVID-19 ARDS. Accordingly,

we have now pivoted remestemcel-L to also target ARDS, the principal cause of death in COVID-19 infection.

Remestemcel-L is being rigorously evaluated in a randomized controlled trial to confirm earlier pilot data showing the therapy's effectiveness to enable gravely ill COVID-19 patients to be taken off ventilators in the shortest timeframe possible.

The results, if positive, of this ongoing 300-patient Phase 3 trial in COVID-19 ARDS patients will build upon the totality of the evidence for the effectiveness of remestemcel-L in adults and children with severe and life-threatening inflammatory conditions. If a survival benefit is confirmed, Mesoblast plans to seek potential approval of this therapy in the highest risk patients. In parallel, we will continue to pursue an accelerated approval pathway for remestemcel-L in the treatment of children with SR-aGVHD, a life-threatening condition with

no approved therapies for those under 12 years of age.

Beyond remestemcel-L, we believe we have developed the most mature and diverse portfolio of cellular medicines for serious acute and chronic inflammatory conditions, and readouts of Phase 3 trials in these additional programs will underpin both our near-term value proposition and our medium to long-term strategic initiatives.

The Board would especially like to highlight the outstanding external and internal leadership displayed by our Chief Executive Dr Silviu Itescu, and the unwavering diligence and work ethic displayed by the entire Mesoblast team during these very difficult times.

We are deeply grateful for the ongoing support of our investors whose continued confidence has provided us with the capital to successfully prosecute our business strategy.

Sincerely,

Joseph R. Swedish

Chairman

MESOBLAST LIMITED 2020 ANNUAL REPORT 1

FORM 20-F

  • MESOBLAST LIMITED 2020 ANNUAL REPORT

This is an excerpt of the original content. To continue reading it, access the original document here.

Disclaimer

Mesoblast Limited published this content on 26 October 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 26 October 2020 04:44:05 UTC


© Publicnow 2020
All news about MESOBLAST LIMITED
11/24MESOBLAST : Chairman Message to 2020 AGM
AQ
11/24MESOBLAST : Results of Meeting
PU
11/24MESOBLAST : Chairman Message to 2020 AGM
PU
11/24MESOBLAST : CEO Presentation to 2020 Annual General Meeting
PU
11/23MESOBLAST : Corporate Update and Financial Results Webcast
AQ
11/23MESOBLAST : Novartis and Mesoblast Remestemcel-L Collaboration
AQ
11/23MESOBLAST LIMITED : - Q1 FY 2021 Financial Results and Operational Highlights
AQ
11/20MESOBLAST : Novartis signs $50 million deal for Mesoblast cell therapy for COVID..
RE
11/20Australia shares snap four-day rally as virus outbreaks weigh
RE
11/19MESOBLAST : Up 25% After Hours on Collaboration With Novartis
DJ
More news
Financials
Sales 2021 165 M 121 M 121 M
Net income 2021 -24,4 M -18,0 M -18,0 M
Net cash 2021 35,5 M 26,1 M 26,1 M
P/E ratio 2021 -89,9x
Yield 2021 -
Capitalization 2 431 M 1 787 M 1 786 M
EV / Sales 2021 14,5x
EV / Sales 2022 9,42x
Nbr of Employees 102
Free-Float 77,4%
Chart MESOBLAST LIMITED
Duration : Period :
Mesoblast Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MESOBLAST LIMITED
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 6
Average target price 4,16 AUD
Last Close Price 4,47 AUD
Spread / Highest target 56,6%
Spread / Average Target -6,94%
Spread / Lowest Target -62,4%
EPS Revisions
Managers
NameTitle
Silviu Itescu Chief Executive Officer, MD & Executive Director
Joseph R. Swedish Independent Non-Executive Chairman
Dagmar Rosa-Bjorkeson Chief Operating Officer
Joshua Muntner Chief Financial Officer
Paul Simmons Head-Research & New Product Development
Sector and Competitors
1st jan.Capitalization (M$)
MESOBLAST LIMITED114.90%1 925
LONZA GROUP AG56.17%44 950
MODERNA, INC.403.89%39 001
CELLTRION, INC.66.57%36 284
IQVIA HOLDINGS INC.11.32%32 977
SEAGEN INC.44.08%29 684